Inovio Pharma (NASDAQ: INO) announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Mergers and Acquisitions

Inovio Pharmaceuticals (INO) Bullish Stance Reiterated at StifelAugust 10, 2015 11:34 AM Inovio Pharmaceuticals (INO) Overweight Rating, $31 PT Reiterated at Piper Jaffray Amid AstraZeneca DealAugust 10, 2015 11:19 AM Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmuneAugust 10, 2015 3:00 AM Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmuneAugust 10, 2015 3:00 AM